Focus: Illumina is a market-leading provider of genomic sequencing tools, research products, and molecular diagnostics for precision medicine across oncology, infectious diseases, and genetic testing. Founded in 1998 and headquartered in Hayward, CA, the company operates at significant scale with 152 active job openings across multiple functions.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Contracting — net -57 jobs in 30d
143 added, 200 removed. Active reduction in progress.
5 recent layoff filings (12 mo) — 16 affected
Source: state DOL filings via Big Local News
Illumina offers strong technical depth and growth opportunity in genomics-driven diagnostics, ideal for engineers and commercial professionals but may disappoint those seeking traditional drug development experience.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Clinical diagnostic test leveraging genomic risk assessment for preventive cardiovascular medicine.
Help build intelligence for Illumina
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Illumina's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Oncology diagnostic platform enabling tumor sequencing and treatment selection across multiple cancer types.
NGS-based diagnostic assay for COVID-19 detection, demonstrating infectious disease diagnostic capability.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
No reported FDA warnings, WARN Act filings, or product shortages indicate stable operational footing with no immediate restructuring signals.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo